Biosimilars in the EU
Information guide for healthcare professionals Biosimilars in the EU Prepared jointly by the European Medicines Agency and the European Commission
Download Biosimilars in the EU
Information
Domain:
Source:
Link to this page:
Documents from same domain
Q12 Step 2b Technical and regulatory …
www.ema.europa.euICH guideline Q12 on technical and regulatory considerations for pharmaceutical product lifecycle management EMA/CHMP/ICH/804273/2017 Page 3/36
Guideline on good pharmacovigilance practices …
www.ema.europa.eu9 December 2013 . EMA/816292/2011 Rev 1* Guideline on good pharmacovigilance practices (GVP) Module VII – Periodic safety update report (Rev 1)
Guideline on good pharmacovigilance practices (GVP)
www.ema.europa.euGuideline on good pharmacovigilance practices (GVP) – Module IX (Rev 1) EMA/827661/2011 Rev 1 Page 2/25
Guideline on good pharmacovigilance practices …
www.ema.europa.euGuideline on good pharmacovigilance practices (GVP) – Module VIII (Rev 3) EMA/813938/2011 Rev 3 Page 2/28
Guideline for good clinical practice E6(R2)
www.ema.europa.euGuideline for good clinical practice E6(R2) EMA/CHMP/ICH/135/1995 Page 2/70 Document History First Codification History Date New Codification
Guideline for good clinical practice E6(R2)
www.ema.europa.euGuideline for good clinical practice E6(R2) EMA/CHMP/ICH/135/1995 Page 2/75 10 Document History 11 First Codification History Date New Codification November
Guideline on good pharmacovigilance practices …
www.ema.europa.euharmful physical or psychological effects [DIR 2001/83/EC Art 1(1 6)]. 74 Adverse event (AE); synonym: Adverse experience 75 Any untoward medical occurrence in a patient or clinical- trial subject administered a medicinal product
European Medicines Agency
www.ema.europa.eu© EMEA 2006 2 SPECIFICATIONS: TEST PROCEDURES AND ACCEPTANCE CRITERIA FOR BIOTECHNOLOGICAL/BIOLOGICAL PRODUCTS ICH Harmonised Tripartite Guideline
products1/traditional herbal medicinal products
www.ema.europa.euThere is no expectation that existing herbal medicinal products on the market will be affected by this guideline, with the exception of traditional herbal medicinal products for human use that were already
Q7 Q&A - good manufacturing practice for active ...
www.ema.europa.euICH guideline Q7 on good manufacturing practice for active pharmaceutical ingredients – questions and answers EMA/CHMP/ICH/468930/2015 Page 2/37
Related documents
Biosimilars, Oxidative Damage, and Unwanted …
www.bioprocessintl.com28 BioProcess International 11(6)s Ju n e 2013 Supplement B i o s i m i l a r s Technical Biosimilars, Oxidative Damage, and Unwanted Immunogenicity A Review by Edward T. Maggio C oncerns about the economic viability of biosimilars center
FIRST DRAFT Guideline on clinical evaluation of …
www.ema.europa.euGuideline on clinical evaluation of vaccines EMEA/CHMP/VWP/164653/05 Rev. 1 Page 6/21 165 4. Immunogenicity 166 4.1. Characterisation of the immune response
New Zealand Data Sheet - Medsafe
www.medsafe.govt.nzNew Zealand Data Sheet Page 1 of 7 DUKORAL®. Vibrio cholerae. and enterotoxigenic . Escherichia coli. vaccine . Name of the Medicine . Vaccine containing heat inactivated Vibrio cholerae O1 Inaba classic strain, formalin inactivated Vibrio cholerae O1 Inaba El Tor strain, heat inactivated Vibrio cholerae O1 Ogawa classic strain, formalin …
HIGHLIGHTS OF PRESCRIBING INFORMATION …
www.merck.comHIGHLIGHTS OF PRESCRIBING INFORMATION These highlights do not include all the information needed to use RECOMBIVAX HB safely and effectively. See full prescribing
Guidelines on Clinical Evaluation of Vaccines: …
www.who.int1 2 3 WHO/DRAFT/27 January 2016 4 ENGLISH ONLY 5 6 7 Guidelines on Clinical Evaluation of Vaccines: Regulatory Expectations 8 Proposed revision of WHO TRS 924, Annex 1 9 10 NOTE: 11 12 This document has been prepared for the purpose of inviting comments and suggestions on the proposals 13 contained therein, which will …
Annex 4 - WHO
www.who.int153 Annex 4 Recommendations to assure the quality, safety and efficacy of influenza vaccines (human, live attenuated) for intranasal administration
Morbidity and Mortality Weekly Report
www.cdc.govMorbidity and Mortality Weekly Report Recommendations and Reports June 22, 2007 / Vol. 56 / No. RR-4 INSIDE: Continuing Education Examination depardepardepartment of health and human servicesvicesvices